Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Rituximab as an effective and probably safe treatment for granulomatosis with polyangiitis (Wegener's Granulomatosis).

Tavakolpour S, Alesaeidi S.

Int Immunopharmacol. 2019 Feb 20;70:67-68. doi: 10.1016/j.intimp.2019.01.029. [Epub ahead of print] No abstract available.

PMID:
30785092
2.

"Change over time in the treatment of pemphigus vulgaris between 2004 and 2016 in Iran": A multiple cross-sectional study.

Salarvand F, Fatehi Z, Shahali M, Balighi K, Ghiasi M, Abedini R, Mahmoudi H, Tavakolpour S, Chams-Davatchi C, Daneshpazhooh M.

Dermatol Ther. 2019 Jan 18:e12827. doi: 10.1111/dth.12827. [Epub ahead of print] No abstract available.

PMID:
30659718
3.

Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?

Balighi K, Daneshpazhooh M, Mahmoudi H, Badakhsh M, Teimourpour A, Ehsani AH, Azizpour A, Akbari Z, Mahdavinia M, Ghasemiadl M, Tavakolpour S.

Arch Dermatol Res. 2019 Jan;311(1):63-69. doi: 10.1007/s00403-018-1881-1. Epub 2018 Dec 1.

PMID:
30506422
4.

Lichen planopilaris: Retrospective study on the characteristics and treatment of 291 patients.

Babahosseini H, Tavakolpour S, Mahmoudi H, Balighi K, Teimourpour A, Ghodsi SZ, Abedini R, Ghandi N, Lajevardi V, Kiani A, Kamyab K, Mohammadi M, Daneshpazhooh M.

J Dermatolog Treat. 2018 Nov 9:1-28. doi: 10.1080/09546634.2018.1542480. [Epub ahead of print]

PMID:
30411987
5.

Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab.

Balighi K, Sakhi RS, Daneshpazhooh M, Mahmoudi H, Teimourpour A, Tavakolpour S.

Dermatol Ther. 2018 Nov;31(6):e12671. doi: 10.1111/dth.12671. Epub 2018 Sep 24. No abstract available.

PMID:
30246907
6.

Coexistence of oral lichen planus and pemphigus vulgaris.

Balighi K, Mahmoudi H, Tavakolpour S, Daneshpazhooh M.

Clin Oral Investig. 2018 Sep 15. doi: 10.1007/s00784-018-2619-3. [Epub ahead of print] No abstract available.

PMID:
30218230
7.

Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.

Tavakolpour S.

Dermatol Ther. 2018 Sep;31(5):e12696. doi: 10.1111/dth.12696. Epub 2018 Sep 11.

PMID:
30207045
8.

Trichloroacetic acid as a treatment for persistent oral mucosal lesions in pemphigus vulgaris.

Mahmoudi H, Balighi K, Tavakolpour S, Daneshpazhooh M, Chams-Davatchi C.

J Am Acad Dermatol. 2019 Mar;80(3):e51-e52. doi: 10.1016/j.jaad.2018.08.039. Epub 2018 Sep 6. No abstract available.

PMID:
30195574
9.

Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.

Balighi K, Daneshpazhooh M, Akbari Z, Tavakolpour S, Azimi P, Azizpour A.

J Dermatolog Treat. 2018 Sep 12:1-4. doi: 10.1080/09546634.2018.1509049. [Epub ahead of print]

PMID:
30081690
10.

Oral Candida colonization and plaque type psoriasis: Is there any relationship?

Lesan S, Toosi R, Aliakbarzadeh R, Daneshpazhooh M, Mahmoudi L, Tavakolpour S, Mahmoudi H.

J Investig Clin Dent. 2018 Aug;9(3):e12335. doi: 10.1111/jicd.12335. Epub 2018 Mar 30.

PMID:
29603683
11.

Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.

Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M.

Int Immunopharmacol. 2018 Jan;54:131-138. doi: 10.1016/j.intimp.2017.11.005. Epub 2017 Nov 10. Review.

PMID:
29132070
12.

Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus.

Tavakolpour S.

Arch Dermatol Res. 2018 Mar;310(2):95-106. doi: 10.1007/s00403-017-1790-8. Epub 2017 Nov 6. Review.

PMID:
29110080
13.

Corrigendum to "The possible role of interleukin-35 and its therapeutic potential in pemphigus" [Int. Immunol. 42 (2017) 11-17].

Tavakolpour S, Kheiry F, SadatMirsafaei H, Akhlaghdoust M.

Int Immunopharmacol. 2018 Apr;57:200. doi: 10.1016/j.intimp.2017.10.031. Epub 2017 Nov 4. No abstract available.

PMID:
29108872
14.

Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?

Tavakolpour S.

Int Immunopharmacol. 2017 Dec;53:133-142. doi: 10.1016/j.intimp.2017.10.027. Review.

PMID:
29107213
15.

Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review.

Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M.

Infect Dis (Lond). 2018 Feb;50(2):95-106. doi: 10.1080/23744235.2017.1384957. Epub 2017 Oct 11.

PMID:
29020844
16.

Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy.

Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S.

Immunol Lett. 2017 Oct;190:206-212. doi: 10.1016/j.imlet.2017.08.003. Epub 2017 Aug 5. Review.

PMID:
28827021
17.

Towards personalized medicine for patients with autoimmune diseases: Opportunities and challenges.

Tavakolpour S.

Immunol Lett. 2017 Oct;190:130-138. doi: 10.1016/j.imlet.2017.08.002. Epub 2017 Aug 8. Review.

PMID:
28797806
18.

Rituximab administration in a patient with pemphigus vulgaris following reactivation of occult hepatitis B virus infection.

Tavakolpour S, Soori T, Noormohammadpour P, Balighi K, Mahmoudi H, Daneshpazhooh M.

Dermatol Online J. 2017 Jun 20;23(6). pii: 13030/qt8927s9kt.

19.

The ignored roles of microRNAs in alopecia areata.

Tavakolpour S, Elkaei Behjati S.

Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12488. Epub 2017 Apr 12. No abstract available.

PMID:
28401623
20.

Comparison of Vitamin D Levels in Naive, Treated, and Inactive Carriers with Chronic Hepatitis B Virus.

Sali S, Tavakolpour S, Farkhondemehr B.

J Clin Transl Hepatol. 2016 Dec 28;4(4):306-309. doi: 10.14218/JCTH.2016.00037. Epub 2016 Dec 27.

21.
22.

Management of pemphigus disease in pregnancy.

Tavakolpour S, Mirsafaei HS, Delshad S.

Am J Reprod Immunol. 2017 Jan;77(1). doi: 10.1111/aji.12601. Epub 2016 Nov 8. Review.

PMID:
27862562
23.

The possible role of interleukin-35 and its therapeutic potential in pemphigus.

Tavakolpour S, Kheiry F, Mirsafaei HS, Akhlaghdoust M.

Int Immunopharmacol. 2017 Jan;42:11-17. doi: 10.1016/j.intimp.2016.11.005. Epub 2016 Nov 14. Review. Erratum in: Int Immunopharmacol. 2018 Apr;57:200.

PMID:
27855302
24.

Changes in induced regulatory T cells by interleukin 35 during atopic dermatitis.

Tavakolpour S.

An Bras Dermatol. 2016 Sep-Oct;91(5):703. doi: 10.1590/abd1806-4841.20165504. No abstract available.

25.

Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection.

Tavakolpour S, Alavian SM, Sali S.

Hepat Mon. 2016 May 25;16(6):e37927. doi: 10.5812/hepatmon.37927. eCollection 2016 Jun.

26.

Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis.

Tavakolpour S.

Mult Scler Relat Disord. 2016 Jul;8:66-73. doi: 10.1016/j.msard.2016.05.001. Epub 2016 May 2. Review.

PMID:
27456877
27.

New Insights into the Management of Patients with Autoimmune Diseases or Inflammatory Disorders During Pregnancy.

Tavakolpour S, Rahimzadeh G.

Scand J Immunol. 2016 Sep;84(3):146-9. doi: 10.1111/sji.12453. Review.

28.

Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened.

Tavakolpour S, Alavian SM, Sali S.

Hepat Mon. 2016 Mar 26;16(4):e35810. doi: 10.5812/hepatmon.35810. eCollection 2016 Apr. Review.

29.

Tumor Necrosis Factor-α-308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis.

Tavakolpour S, Sali S.

Hepat Mon. 2016 Apr 12;16(4):e33537. doi: 10.5812/hepatmon.33537. eCollection 2016 Apr. Review.

30.

The dual nature of retinoic acid in pemphigus and its therapeutic potential: Special focus on all-trans Retinoic Acid.

Tavakolpour S, Daneshpazhooh M, Mahmoudi HR, Balighi K.

Int Immunopharmacol. 2016 Jul;36:180-186. doi: 10.1016/j.intimp.2016.04.031. Epub 2016 May 5. Review.

PMID:
27156125
31.

Association of Plasma Levels of Vitamin D With Chronic Hepatitis B Infection.

Tavakolpour S, Sali S, Gachkar L.

Hepat Mon. 2016 Jan 16;16(1):e35525. doi: 10.5812/hepatmon.35525. eCollection 2016 Jan. No abstract available.

32.

Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?

Tavakolpour S.

Int Immunopharmacol. 2016 May;34:139-145. doi: 10.1016/j.intimp.2016.02.020. Epub 2016 Mar 3. Review.

PMID:
26945832
33.

The new insight into management of hepatitis B virus patients with flare.

Tavakolpour S.

Immunol Lett. 2016 May;173:77. doi: 10.1016/j.imlet.2016.02.008. Epub 2016 Feb 20. No abstract available.

PMID:
26903195
34.

Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.

Tavakolpour S.

Dermatol Ther. 2016 Sep;29(5):299. doi: 10.1111/dth.12327. Epub 2016 Jan 22. No abstract available.

PMID:
26800435
35.

Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients.

Tavakolpour S.

Immunol Lett. 2016 Mar;171:70-1. doi: 10.1016/j.imlet.2015.12.007. Epub 2015 Dec 28. No abstract available.

PMID:
26730847
36.

Interleukin 4 inhibition as a potential therapeutic in pemphigus.

Tavakolpour S, Tavakolpour V.

Cytokine. 2016 Jan;77:189-95. doi: 10.1016/j.cyto.2015.09.017. Epub 2015 Oct 2. Review.

PMID:
26440137

Supplemental Content

Loading ...
Support Center